Background: To identify a serum prolactin (PRL) cut-off value indicative of a
| INTRODUCTION
Polycystic ovary syndrome (PCOS) is the commonest endocrinopathy in women of reproductive age with a prevalence of 6%-10%. [1] [2] [3] Chronic oligo-anovulation and hyperandrogenism constitute the cardinal features of PCOS, while insulin resistance and hyperinsulinaemia contribute substantially to its pathogenesis, clinical/biochemical manifestations and long-term sequelae. 4 Current guidelines endorse the use of the Rotterdam criteria for diagnosing PCOS. 5 Elevated prolactin (PRL) levels have been reported with a prevalence ranging between 7 and 52% in PCOS attributed to the abnormal hormonal milieu as well as a relative dopamine deficiency. [6] [7] [8] [9] [10] [11] Hyperprolactinaemia is also common in women of reproductive age 12 and may mimic the clinical phenotype of PCOS. 6, 13, 14 Prolactinomas are the most frequent cause of nonpuerperal endogenous hyperprolactinaemia, accounting for 40% of all pituitary adenomas. 14 Although PRL levels >250 ng/mL are highly indicative of a prolactinoma, a significant number of patients with mildto-moderate elevations of PRL may still harbour a prolactinoma after excluding other causes of hypeprolactinemia. 13, 14 This is particularly relevant in patients with PCOS and concomitant hyperprolactinaemia as pathophysiology and their treatment may be different compared to normoprolactinemic PCOS. 10, 15, 16 Magnetic resonance imaging (MRI) is the modality of choice for diagnosizing pituitary adenomas, especially microadenomas. 13 However, it has not been substantiated whether hypeprolactinemic PCOS patients should undergo pituitary MRI to exclude a prolactinoma based on serum PRL concentrations. This is of relevance as the presence of a pituitary microadenoma on pituitary MRI in PCOS patients with moderately elevated PRL concentrations may well represent an incidentaloma. There is currently a paucity of data on the association between PCOS and prolactinomas. 10, 17 In addition, as there is no clear cut-off value of serum PRL level that could be used to distinguish between functional hyperprolactinaemia and the presence of a prolactinoma in PCOS, the criteria for further evaluation of such patients with pituitary imaging rely largely upon each clinician's threshold.
The aim of the present retrospective case-control study was the identification of a serum PRL cut-off value above which a pituitary MRI could be justifiable in hyperprolactinaemic PCOS patients. We also aimed to identify clinical, metabolic and endocrine features of patients with PCOS and microprolactinomas and compare them to those of patients with PCOS and hyperprolactinaemia without adenoma and normoprolactinemic PCOS subjects.
| MATERIALS AND METHODS
We retrospectively reviewed the records of 620 patients who attended the General Endocrine and PCOS Outpatient clinics at WISDEM Centre (Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism) and Centre for Reproductive Medicine (CRM), University Hospitals Coventry and Warwickshire NHS Trust (UHCW) for menstrual disorders, infertility or hirsutism between 2002 and 2016. The study was approved by the UHCW audit Department.
Of 620 patients, 528 met at least two out of the three Rotterdam criteria for the diagnosis of PCOS, in the absence of other conditions with PCOS-like phenotype. 5, 18 Patients without serum PRL measurement were excluded ( Figure 1) .
Hyperprolactinaemia, defined as PRL levels greater than the upper limit of normal 14 (UNL >23.6 ng/mL) in at least two different samples collected on two different days, was found in 76 patients (14.4%). Of these 76 patients, 16 were excluded as hyperprolactinaemia was attributed to another pathology (12 patients were receiving medications known to affect PRL levels, 2 were pregnant, and 1 had stressrelated hyperprolactinaemia). Screening for macroprolactin was performed in 19 patients with hyperprolactinaemia and normal menstrual cycles and was positive in one. After exclusion of these 16 patients, 60 women were included in the hyperprolactinaemic PCOS group of our study. Further assessment with pituitary MRI was performed in patients with PRL levels ≥94.0 ng/mL, 14 and in those with mild-to-moderate persistent hyperprolactinaemia and concomitant symptoms that could be attributed to a pituitary adenoma such as unaccounted headaches, prolonged amenorrhea and/or galactorrhoea. The diagnosis of prolactinoma was made in patients with hyperprolactinaemia who had an MRI-identifiable pituitary adenoma that responded to treatment with dopamine agonists (DAs) with normalization of PRL levels and substantial reduction in the size or resolution of the adenoma on follow-up MRI scans. 13, 14 Only patients with microprolactinomas (measuring <10 mm) were included in our analysis. Subjects with adenomas who showed no response to treatment with DAs or other MRI abnormalities were excluded.
| Clinical parameters
Data collected included: age, body mass index (BMI = Kg/ m 2 ), the presence of hirsutism/acne, galactorrhoea and menstrual history. Oligomenorrhoea was defined as cycles occurring at intervals greater than 35 days or <8 menstrual cycles per year. Amenorrhea was defined as the absence of menstrual cycles for more than 6 months. 
| Biochemical parameters
Fasting blood samples were obtained in the morning during early follicular phase in patients with regular menstrual cycles, 2 days after a 7-day progesterone-only pill course in patients with oligomenorrhoea or randomly in patients with amenorrhea.
The following parameters were recorded: serum concentrations of cholesterol, glycated haemoglobin A1c (HbA1c), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), PRL, testosterone, dehydroepiandrosterone sulphate (DHEA-S), oestradiol (E 2 ), sex hormone-binding globulin (SHBG). Free-androgen index (FAI) was calculated as follows: total testosterone (nmol/L) 9 100/SHBG (nmol/L). 2.3 | Assays PRL was measured using Prolactin II on Roche cobas e 602, which is a sandwich electrochemiluminescence immunoassay. The manufacturer states the assay has the following precision: 1.8% at 13.6 ng/mL, 1.4% at 41.1 ng/ mL and 1.6% at 211.2 ng/mL. The laboratory has also established its own precision data: 1.97% at 2.0 ng/mL, 1.94% at 36.5 ng/mL and 1.59% at 83.2 ng/mL.
| Other measurements
Assays were performed using an automated analyzer (Abbott Architect; Abbott Laboratories, Abbott Park, IL).
| Imaging studies
Gadolinium-enhanced MRI scans of the pituitary were performed at the radiology department and were reviewed by the same radiologist (HM).
Firstly, we aimed to identify a threshold for serum PRL that could distinguish hyperprolactinaemic PCOS patients with microprolactinomas from those without. We also compared the clinical, metabolic and endocrine parameters of patients with PCOS and microprolactinomas (Group A) to those of patients with PCOS, hyperprolactinaemia and normal MRI findings (Group B) and age-and BMI-matched PCOS patients with normal PRL levels (Group C).
| Statistical analysis
Comparisons of categorical variables between groups were performed using Fisher's exact test. The non-parametric Mann-Whitney U test was used to compare not normally distributed continuous variables between two groups. Comparisons between three groups were assessed using the one-way ANOVA and Kruskal-Wallis tests, for normally and not-normally distributed variables, respectively. The results were presented as (i) mean AE SD or median (range) for continuous variables with or without normal distribution, respectively, (ii) frequency for categorical variables. Statistical analyses were performed using the statistical package PRISM 7. P-values < .05 were considered as statistically significant. Receiver operating characteristic (ROC) curve analysis was performed in order to determine the cut-off value for serum PRL levels.
| RESULTS
Of 60 patients with PCOS and concomitant hyperprolactinaemia, 44 (73.3%) underwent MRI of the pituitary: 8/44 patients had serum PRL levels ≥94.0 ng/mL (range: 94.0-351.5 ng/mL) and 36/44 had mild-moderate hyperprolactinaemia (PRL range: 25.3-93.7 ng/mL) and symptoms suspicious of a pituitary adenoma as previously defined. Four patients had minimal PRL elevations (25.3-31.1 ng/mL) and were imaged due to persistent headache and prolonged amenorrhea.
Of the remaining 16 patients, 14 displayed mild increases in their serum PRL levels (range: 23.8-35.4 ng/ mL) in the absence of associated symptoms. A further 2 patients were claustrophobic and were unable to undergo MRI (PRL levels 47.3 and 51.0 ng/mL, respectively).
Of the 44 hyperprolactinaemic PCOS patients who had pituitary imaging, 19 patients had pituitary adenomas, 18 had normal MRI findings and 7 other abnormalities (1 Rathke's cyst, 1 duplication and thickening of the pituitary stalk, 1 diffusely enlarged pituitary gland, 4 mild asymmetry of the pituitary gland with homogeneous or slightly inhomogeneous enhancement but no focal mass indentified). Median PRL levels in this latter group were 47.3 ng/ mL (range: 39.3-75.3).
Among 19 patients with pituitary adenomas, 17 had microadenomas and 2 macroadenomas. The latter were initially referred for persistent headache, secondary amenorrhea and galactorrhoea and were found to have nonfunctioning pituitary adenomas (NFPA) along with PCOS (PRL: 30.3 and 94.0 ng/mL) and were excluded from the analysis.
Out of 17 patients with microadenomas, 2 did not receive treatment with DAs (PRL: 71.1 and 74.7 ng/mL) and 2 showed no radiological response to treatment with DAs, that is no reduction in tumour size on follow-up MRI scans besides normalization of their PRL levels (baseline PRL: 74.2 and 49.0 ng/mL). Thus, the diagnosis of a microprolactinoma could not be established based on the previously mentioned criteria and were excluded from analysis.
The remaining 13 women consisted Group A of our study, that is PCOS patients with elevated PRL levels due to concomitant microprolactinomas (Figure 1 ). Median PRL levels in this patient group were 95.4 ng/mL (range: 48.3-351.5) ( Table 2) . Following initiation of treatment with DAs, all these patients with a provisional diagnosis of a prolactinoma obtained normalization/substantial reduction in their PRL levels along with a significant tumour reduction (n = 9/13, 69.2%, median reduction: 47.2%, range: 25-100%) or resolution (n = 4/13) of the previously noted pituitary adenoma.
Group B of our study consisted of 18 hyperprolactinaemic PCOS subjects who had normal pituitary MRI (Figure 1) . Median PRL levels in this patient group were 49.2 ng/mL (range: 25.3-84.3; Table 2 ).
A further 30 age-and BMI-matched patients with PCOS and normal PRL levels (Group C) formed our control group.
| Distribution of PRL levels in patients with PCOS and hyperprolactinaemia and PRL thresholds as predictors of prolactinomas
Pituitary adenomas were identified in 33.3% of patients with PRL levels ranging between 47.2 and 70.8 ng/mL (2/ 6), 44.4% with PRL levels between 70.8 and 94.0 ng/mL (4/9) and 100% with PRL levels ≥94.0 ng/mL (7/7). None of the patients with PRL values less than 47.2 ng/mL had an identifiable adenoma on MRI scan.
Patients harbouring prolactinomas had significantly higher PRL levels compared to patients with no adenomas (P < .0001; Table 2 ). Following initiation of treatment with DAs patients with prolactinomas responded with normalization or substantial decrease in serum PRL levels (median PRL post-treatment: 14.7 ng/mL, range: 1.2-26.4) and significant reduction in the size of adenoma on follow-up MRI scans (median pituitary adenoma size, pre-vs posttreatment: 7.7 vs 2.5 mm, P = .005) ( Table 1) .
ROC curve analysis was performed to determine a cutoff value of serum PRL that could identify hyperprolactinaemic PCOS subjects with adenomas. The area under the curve (AUC) value was 0.91, indicating a high accuracy. Several PRL cut-off values were analysed to obtain acceptable sensitivity and specificity. A cut-off PRL value of 47.5 ng/mL could correctly identify all patients with prolactinomas, albeit with a low specificity (50%), as 9 of 18 patients with no identifiable adenoma had PRL levels higher than 47.5 ng/mL [positive and negative predictive value (PPV) of 59.1% and (NPV) of 100%, respectively]. A PRL threshold of 85.2 ng/mL could distinguish patients with prolactinomas with a sensitivity of 77% and a high specificity of 100% [AUC (95%) = 0.91(0.8-1.018), P = .0001] (PPV and NPV were 100% and 85.7%, respectively, diagnostic accuracy: 90.3%) [ Figure 2 (Α) and (Β)].
| Comparisons between Groups A, B and C
Clinical, metabolic and endocrine features of patients in Groups A, B and C are shown in Tables 1 and 2 . 
T A B L E 1 Baseline clinical and imaging characteristics in 3 PCOS study groups

Group
| Clinical parameters
Women in Group A were younger compared to women in Group B (P = .03) ( Table 1) . No differences were observed in the frequency of clinical hyperandrogenism, menstrual irregularities or PCO morphology between the three groups and BMI or the frequency of galactorrhoea between Groups A and B.
| Metabolic and endocrine parameters
Serum PRL levels (pre-treatment) were significantly higher in Group A compared to Group B (P < .0001). In addition, LH levels were significantly lower in Group A compared to Groups B and C (A vs B: P = .0063, A vs C: P = .0001) (Figure 3 ). No differences were observed between the three groups with respect to biochemical and/ or endocrine parameters (Table 2 ).
| DISCUSSION
The association between PCOS and prolactinoma was first described in 1979 in three patients presenting with hyperprolactinaemia, infertility, a pituitary tumour and bilateral wedge resection of the ovaries for PCOS. 20 Subsequently, further patients with galactorrhoea, mildly elevated PRL levels and history of PCOS, were found to have prolactinomas. 21, 22 Since then, the frequency of pituitary adenomas among patients with PCOS and elevated PRL levels has been mentioned in only few small studies, overall ranging between 10 and 69%. 7, 10, 23, 24 In our study, prolactinomas were identified in 21.7% of patients with PCOS and hyperprolactinaemia and in 2.46% of all PCOS patients. Of note, the prevalence of ever treated hyperprolactinaemia among female patients in a large cohort of patients in the Netherlands was 93.9/ 100 000 inhabitants. 25 Thus, the association between PCOS and prolactinomas may not be a rare entity. However, there is limited information regarding the range of PRL levels in hyperprolactinaemic PCOS patients and the prevalence of prolactinomas. Mild hyperprolactinaemia in the absence of prolactinoma has been described in association with PCOS with a variable prevalence, mean PRL values ranging from 25.5 AE 2.2 to 40.3 AE 18.4 ng/mL and has been mainly attributed to a relative dopamine deficiency and the abnormal hormonal milieu. [6] [7] [8] [9] [10] [11] 26 Our analysis showed, that PCOS patients with prolactinomas had significantly higher PRL levels than hyperprolactinaemic PCOS patients without adenomas (median PRL 95.4 vs 49.2 ng/mL, P < .0001). In addition, PRL levels ≥94.0 ng/mL were associated with prolactinomas in all cases. These findings are in accordance with previous studies, 27, 28 suggesting that when other causes of hyperprolactinaemia are excluded, PRL levels ≥4 9 upper normal limit make the possibility of functional hyperprolactinaemia highly unlikely among PCOS patients and thus warrant further imaging investigations. We tried to establish a cut-off PRL level that could predict the presence of a prolactinoma. A cut-off PRL value of 47.5 ng/mL could reliably identify all patients with PCOS and coexisting microadenomas albeit with low specificity and PPV of 59.1%, suggesting that a considerable number of women with PRL levels >47.5 ng/mL have no pituitary adenoma on MRI. Alternatively, PRL levels >85.2 ng/mL were associated with a 100% specificity and 77% sensitivity for discriminating hyperprolactinaemic PCOS patients with prolactinomas from those without, as reflected by a high PPV of 100% and an acceptable NPV of 85.7%. [20] [21] [22] an association between estrogens and the formation of prolactinomas or an increase in their volume is less clear. 29 In addition, elevated PRL levels have been associated with alterations in steroidogenic enzyme activities, increased androgen production, insulin resistance, hirsutism and PCO morphology, 6,30-33 all of the above being essential components of the PCOS phenotype. PCOS patients with prolactinomas had significantly lower LH levels compared to hyperprolactinaemic PCOS patients without adenomas and normoprolactinemic PCOS. This finding may suggest that patients with PCOS and concomitant prolactinoma may have a different gonadotrophin profile from the "classic PCOS," which is often associated with LH excess. 20, 22 In addition, women with PCOS and prolactinomas were younger than hyperprolactinaemic PCOS patients without adenomas. The main strength of the present study is that we accumulated data from a large number of unselected and wellcharacterized patients with PCOS. To our knowledge, this is the first study aiming to delineate the clinical and biochemical profile of patients with PCOS and concurrent prolactinoma although there are some limitations with regard to the study design. Firstly, it is possible that the diagnosis of prolactinoma may have been missed in some cases, as 44 of 60 hyperprolactinaemic PCOS subjects were evaluated with pituitary MRI. However, the remaining patients presented mainly with mild elevations of PRL levels in the absence of symptoms, pointing towards functional hyperprolactinaemia. Secondly, as this was a retrospective study, we had to deal with missing values in certain clinical and biochemical parameters and thus exclude them from our analysis. Furthermore, the number of patients with prolactinomas in both groups was relatively small. Similarly, larger studies are required to establish a cut-off level of serum PRL that could more accurately discriminate prolactinomas from functional hyperprolactinaemia in patients with PCOS.
In conclusion, PRL levels exceeding 85.2 ng/mL in women with PCOS are suggestive of a PRL-producing adenoma and warrant pituitary imaging. In addition, pituitary MRI could be justifiable in young PCOS patients with milder PRL elevation, low LH levels and concomitant symptoms suspicious of a pituitary adenoma. Further studies are needed to better elucidate the pathophysiological mechanisms linking PCOS and prolactinoma.
